Foghorn Therapeutics Inc.
FHTX
$6.26
-$0.23-3.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 112.68% | -45.11% | 223.77% | 4.42% | 9.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 112.68% | -45.11% | 223.77% | 4.42% | 9.71% |
| Cost of Revenue | -15.00% | -15.57% | 7.50% | -18.98% | -8.43% |
| Gross Profit | 82.78% | 4.35% | 27.49% | 29.81% | 15.81% |
| SG&A Expenses | -7.40% | -9.09% | 6.99% | -4.58% | -6.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.18% | -13.94% | 7.38% | -15.81% | -7.93% |
| Operating Income | 58.26% | 5.85% | 18.37% | 22.43% | 12.94% |
| Income Before Tax | 59.91% | -5.53% | -11.08% | 17.12% | 21.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 59.91% | -5.53% | -11.08% | 17.12% | 21.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.91% | -5.53% | -11.08% | 17.12% | 21.95% |
| EBIT | 58.26% | 5.85% | 18.37% | 22.43% | 12.94% |
| EBITDA | 57.65% | 3.40% | 19.14% | 23.66% | 13.64% |
| EPS Basic | 64.26% | 4.64% | -10.74% | 17.65% | 36.07% |
| Normalized Basic EPS | 64.27% | 4.64% | 11.14% | 17.65% | 28.63% |
| EPS Diluted | 64.26% | 4.64% | -10.74% | 17.65% | 36.07% |
| Normalized Diluted EPS | 64.27% | 4.64% | 11.14% | 17.65% | 28.63% |
| Average Basic Shares Outstanding | 12.15% | 10.65% | 0.31% | 0.68% | 22.10% |
| Average Diluted Shares Outstanding | 12.15% | 10.65% | 0.31% | 0.68% | 22.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |